Last week, Zydus entered into an agreement to acquire US-based pharma company Assertio Holdings for $166.40 million. The acquisition provides Zydus with an established US specialty oncology commercial platform, anchored by Assertio’s presence in oncology supportive care. Zydus intends to leverage Assertio’s focused commercial infrastructure and oncology relationships to build and expand its specialty oncology presence in the US.
The management described the proposed acquisition of Assertio Holdings as a “pivotal move” to build a differentiated, high-margin specialty oncology business in the US, anchored by Rolvedon, a long-acting biologic for oncology supportive care.
Zydus reported a 16% year-on-year increase in revenue from operations during the fourth quarter of 2025-26 to Rs 7,587 crore, while net profit rose about 9% to Rs 1,272.50 crore, driven by growth across domestic formulations, consumer wellness and international markets.
The Ahmedabad-based pharmaceutical firm’s adjusted net profit for the quarter was up 15% to Rs 1,592.90 crore, factoring in a one-time expense of Rs 397.50 crore towards a Mirabegron litigation settlement, impact of new labour code and other exceptional costs.
Growth during the quarter was led by a strong product mix, operating leverage, and forex tailwinds, a company official said over an earnings call.
Research and development investments for the quarter stood at Rs 698.20 crore, more than 9% of revenue. Earnings before interest, taxes, depreciation and amortisation (Ebitda) for the March quarter stood at Rs 2,554.40 crore, up 20% year-on-year, while Ebitda margin for the quarter stood at 33.7%, an improvement of 110 basis points on a year-on-year basis. A basis point is a hundredth of a percentage point.The company’s board approved Rs 1,100 crore share buyback at a price of Rs 1,150 per share. It also recommended a dividend of 100% for 2025-26.
For the full year 2025-26, revenue from operations was Rs 27,148.40 crore, up 17% over last year, while adjusted net profit increased 15% to Rs 5,456.40 crore.
“We are confident our pipeline will drive overall growth visibility while future growth engines begin to deliver,” said Sharvil Patel, managing director, Zydus Lifesciences. “Our near-term priorities are clear: maintain consistent quality standards, integrate our recent acquisitions, and capture synergies swiftly.”
He added, “Our strong balance sheet ensures we have the flexibility to invest and strengthen our businesses further.”
The company guided for continued high-teen consolidated revenue growth in FY27, supported by momentum across India, international markets, consumer wellness, and specialty businesses.
The company reiterated that its non-generic specialty portfolio — including rare disease, and oncology supportive care assets — is expected to become a meaningful growth driver over the next 3–5 years.